S
Shan Xu
Researcher at Jiangxi Science and Technology Normal University
Publications - 63
Citations - 672
Shan Xu is an academic researcher from Jiangxi Science and Technology Normal University. The author has contributed to research in topics: Chemistry & Apoptosis. The author has an hindex of 14, co-authored 54 publications receiving 429 citations.
Papers
More filters
Journal ArticleDOI
Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold
TL;DR: Structural-activity relationships (SARs) and docking studies indicated that the pyrazole scaffolds exerted key effect on antitumor activities of target compounds.
Journal ArticleDOI
Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα inhibitors.
Wufu Zhu,Wufu Zhu,Chen Chen,Chengyu Sun,Shan Xu,Chunjiang Wu,Fei Lei,Hui Xia,Qidong Tu,Pengwu Zheng +9 more
TL;DR: Structural-activity relationships (SARs) and docking studies indicated that the chromone moiety is necessary for the potent antitumor activity and cytotoxicity of these compounds.
Journal ArticleDOI
Synthesis and anticancer activity of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives bearing chromone moiety.
Chengyu Sun,Chen Chen,Shan Xu,Jianqiang Wang,Yan Zhu,Dejia Kong,Hong Tao,Mengjia Jin,Pengwu Zheng,Wufu Zhu +9 more
TL;DR: The results indicated that the optimized compound 10j showed excellent inhibitory activity and cytotoxicity against mTOR kinase, PI3Kα kinase and five cancer cell lines with IC50 values of 1.1μM, 0.92μM and 8.3μM.
Journal ArticleDOI
Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as mTOR inhibitors
Wufu Zhu,Wufu Zhu,Chengyu Sun,Shan Xu,Chunjiang Wu,Jielian Wu,Mengze Xu,He Zhao,Le Chen,Weipeng Zeng,Pengwu Zheng +10 more
TL;DR: Structural-activity relationships (SARs) and docking studies indicated that the thiopyrano[4,3-d]pyrimidine scaffolds exerted little effect on antitumor activities of target compounds.
Journal ArticleDOI
The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation
TL;DR: The recent advances in medicinal chemistry of fourth-generation EGFR-TKIs are discussed, as well as further discussed the clinical challenges and future prospects of treating patients with EGFR mutations resistant to third-generationEGFR- TKIs.